Bradley Saenger - Feb 27, 2024 Form 4 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Role
Chief Financial Officer
Signature
/s/ Bradley Saenger
Stock symbol
TNXP
Transactions as of
Feb 27, 2024
Transactions value $
$0
Form type
4
Date filed
2/29/2024, 05:07 PM
Previous filing
Feb 24, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNXP Stock Option Award $0 +282K $0.00 282K Feb 27, 2024 Common Stock 282K $0.37 Direct F1, F2
transaction TNXP Stock Option Award $0 +282K $0.00 282K Feb 27, 2024 Common Stock 282K $0.46 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
F2 The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.